Microbiome in early cancer detection –⁠ biomarker potential and limitations

Czech version

Authors: E. Budinská
Authors‘ workplace: RECETOX, PřF MU, Brno
Published in: Klin Onkol 2026; 39(Supplementum 1): 63-66
Category: Review
doi: https://doi.org/10.48095/ccko2026S63

Overview

Background: Microbiome analysis in cancer research has experienced a surge in interest comparable to the introduction of microarrays for tumor gene expression profiling 25 years ago. Associative studies investigating the composition of the microbiome in stool, tumor tissue swabs and tumor biopsies of oncology patients have been conducted across most cancer types, and their number continues to grow. Screening approaches based on non-invasive or minimally invasive sampling, including the analysis of stool, saliva, urine, and buccal and rectal swabs, are from a clinical perspective among the most promising, owing in part to simpler logistics and the possibility of repeated sampling. These types of specimens are commonly used in microbiome studies, making the microbiome an attractive target for both screening and diagnostic applications. Aim: This review aims to summarize current knowledge regarding the potential of the microbiome in the early detection of cancer, emphasizing its clinical applicability and limitations in the context of population-based prevention.

Keywords:

Cancer screening – microbiota – biomarker – metagenome

Sources

1. Dohlman AB, Pan X, Zitvogel L et al. The multi-kingdom cancer microbiome. Nat Microbiol 2025; 10 (10): 2369–2383. doi: 10.1038/s41564-025-02103-7.

2. Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov 2022; 12 (1): 31–46. doi: 10.1158/2159-8290.CD-21-1059.

3. Helmink BA, Khan MA, Hermann A et al. The microbiome, cancer, and cancer therapy. Nat Med 2019; 25 (3): 377–388. doi: 10.1038/s41591-019-0377-7.

4. Kaiko GE, Stappenbeck TS. Host-microbe interactions shaping the gastrointestinal environment. Trends Immunol 2014; 35 (11): 538–548. doi: 10.1016/j.it.2014.08.002.

5. McGuinness AJ, Stinson LF, Snelson M et al. From hype to hope: considerations in conducting robust microbiome science. Brain Behav Immun 2024; 115 : 120–130. doi: 10.1016/j.bbi.2023.09.022.

6. Asnicar F, Manghi P, Fackelmann G et al. Gut micro-organisms associated with health, nutrition and dietary interventions. Nature 2026; 650 (8101): 450–458. doi: 10.1038/s41586-025-09854-7.

7. Andreu-Sánchez S, Blanco-Míguez A, Wang D et al. Global genetic diversity of human gut microbiome species is related to geographic location and host health. Cell 2025; 188 (15): 3942.e9–3959.e9. doi: 10.1016/j.cell.2025.04.014.

8. Joos R, Boucher K, Lavelle A et al. Examining the healthy human microbiome concept. Nat Rev Microbiol 2025; 23 (3): 192–205. doi: 10.1038/s41579-024-01107-0.

9. Najmanová L, Vídeňská P, Cahová M. Healthy microbiome –⁠ a mere idea or a sound concept? Physiol Res 2022; 71 (6): 719–738. doi: 10.33549/physiolres.934967.

10. Videnska P, Smerkova K, Zwinsova B et al. Stool sampling and DNA isolation kits affect DNA quality and bacterial composition following 16S rRNA gene sequencing using MiSeq illumina platform. Sci Rep 2019; 9 (1): 13837. doi: 10.1038/s41598-019-49520-3.

11. Roume H, Mondot S, Saliou A et al. Multicenter evaluation of gut microbiome profiling by next-generation sequencing reveals major biases in partial-length metabarcoding approach. Sci Rep 2023; 13 (1): 22593. doi: 10.1038/s41598-023-46062-7.

12. Gulyás G, Kakuk B, Dörmö Á et al. Cross-comparison of gut metagenomic profiling strategies. Commun Biol 2024; 7 (1): 1445. doi: 10.1038/s42003-024-07158-6.

13. Piccinno G, Thompson KN, Manghi P et al. Pooled analysis of 3,741 stool metagenomes from 18 cohorts for cross-stage and strain-level reproducible microbial biomarkers of colorectal cancer. Nat Med 2025; 31 (7): 2416–2429. doi: 10.1038/s41591-025-03693-9.

14. Yachida S, Mizutani S, Shiroma H et al. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med 2019; 25 (6): 968–976. doi: 10.1038/s41591-019-0458-7.

15. Zwinsová B, Petrov VA, Hrivňáková M et al. Colorectal tumour mucosa microbiome is enriched in oral pathogens and defines three subtypes that correlate with markers of tumour progression. Cancers (Basel) 2021; 13 (19): 4799. doi: 10.3390/cancers13194799.

16. Poore GD, Kopylova E, Zhu Q et al. Microbiome analyses of blood and tissues suggest cancer diagnostic approach. Matire 2020; 579 (7800): 560–574. doi: 10.1038/s41586-020-2095-1. Retraction in: Nature 2024; 631 (8021): 694. doi: 10.1038/s41586-024-07656-x.

17. Gihawi A, Ge Y, Lu J et al. Major data analysis errors invalidate cancer microbiome findings. mBio 2023; 14 (5): e0160723. doi: 10.1128/mbio.01607-23.

18. Jørgensen AB, Almer L, Brandstrup B et al. Fecal microbiomes from screening sampling tubes are stable despite varying sampling and storage conditions. Sci Rep 2025; 15 (1): 26951. doi: 10.1038/s41598-025-12506-5.